keyword
MENU ▼
Read by QxMD icon Read
search

Oxaliplatin lymphoma

keyword
https://www.readbyqxmd.com/read/29752199/gemcitabine-oxaliplatin-plus-rituximab-r-gemox-as-first-line-treatment-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-single-arm-open-label-phase-2-trial
#1
Qiu-Dan Shen, Hua-Yuan Zhu, Li Wang, Lei Fan, Jin-Hua Liang, Lei Cao, Wei Wu, Yi Xia, Jian-Yong Li, Wei Xu
BACKGROUND: The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma. We aimed to evaluate the efficacy, safety, and feasibility of the R-GemOx regimen as a first-line treatment in elderly patients with diffuse large B-cell lymphoma. METHODS: In this single-arm, open-label, phase 2 clinical trial, we enrolled patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60-69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater...
May 8, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29749542/the-hdac6-inhibitor-acy%C3%A2-1215-enhances-the-anticancer-activity-of-oxaliplatin-in-colorectal-cancer-cells
#2
Dong Hoon Lee, Hye-Rim Won, Hyun-Wook Ryu, Jung Min Han, So Hee Kwon
ACY‑1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. Previous studies have reported that ACY‑1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment. Therefore, the present study aimed to determine whether the synergistic interaction detected between ACY‑1215 and anticancer agents in hematological cancers could occur in solid tumors...
May 11, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29519713/sinusoidal-obstruction-syndrome-veno-occlusive-disease-complication-in-lymphoma-patients-treated-with-oxaliplatin-based-regimen-a-case-series-report
#3
E Bernichon, E Daguenet, C Molla, J Cornillon, C Lejeune, F Casteillo, D Guyotat, E Tavernier
AIM: SOS/VOD is a relevant clinical syndrome that usually appears early after hematopoietic stem cell transplantation. The purpose of this article was to report a case series of SOS/VOD in non-susceptible patients and draw physicians' attention to the plausible relationship between liver injury and oxaliplatin-based chemotherapy, preceding autologous transplantation. METHODS: In this study, we report a case series of SOS/VOD in 4 lymphoma patients following autologous transplantation...
March 5, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29467857/overexpression-of-microrna-15-increases-the-chemosensitivity-of-colon-cancer-cells-to-5-fluorouracil-and-oxaliplatin-by-inhibiting-the-nuclear-factor-%C3%AE%C2%BAb-signalling-pathway-and-inducing-apoptosis
#4
Lili Liu, Dan Wang, Ying Qiu, Hongyan Dong, Xuemei Zhan
Overcoming chemoresistance is a challenge in clinical treatment. It has been reported that microRNAs (miRNAs) are involved in regulating chemosensitivity. Therefore, the present study aimed to identify the effect and mechanism of miR-15 on colon cancer chemotherapy. Reverse transcription-quantitative polymerase chain reaction was performed to measure miR-15 level sin62-paired colon cancer and para-cancerous colon tissues. The overexpression of miR-15 in HCT116 cells was induced by transfection. The effect of miR-15 on the chemosensitivity of colon cancer cells to 5-fluorouracil (5-FU) and Oxaliplatin (OX) was determined using a luminescent cell viability assay...
March 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29316888/the-preventive-effect-of-sensorimotor-and-vibration-exercises-on-the-onset-of-oxaliplatin-or-vinca-alkaloid-induced-peripheral-neuropathies-stop
#5
Fiona Streckmann, Maryam Balke, Helmar C Lehmann, Vanessa Rustler, Christina Koliamitra, Thomas Elter, Michael Hallek, Michael Leitzmann, Tilman Steinmetz, Petra Heinen, Freerk T Baumann, Wilhelm Bloch
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically relevant side effect of chemotherapy. Approximately 50% of all leukemia, lymphoma, colorectal- and breast cancer patients are affected. CIPN is induced by neurotoxic chemotherapeutic agents and can manifest with sensory and/or motor deficits. It is associated with significant disability and poor recovery. Common symptoms include pain, altered sensation, reduced or absent reflexes, muscle weakness, reduced balance control and insecure gait...
January 10, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29070118/-analysis-of-clinical-efficacy-and-influencing-factors-of-gemcitabine-l-asparaginase-oxaliplatin-chemotherapy-scheme-and-radiotherapy-for-treatment-of-early-enktl-patients
#6
Chun Qiu, Lin Wang
OBJECTIVE: To analyse the clinical efficacy and its influencing factors of early ENKTL patients received chemotherapy of gemcitabine-L-asparaginase-oxaliplatin (GELOX) scheme and radiotherapy. METHODS: The clinical data of 80 cases of early nasal type NK/T cell lymphoma treated during May 2013 to May 2016 were analyzed retrospectively. The earty ENKTL patients were divided into 3 groups: group I (50 cases) with GELOX after chemotherapy combined with radical radiotherapy, group II (16 cases) with GELOX after other chemotherapy combined radical radiotherapy, group III (14 cases) patients only received GELOX chemotherapy...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29070117/-efficacy-analysis-of-gemox-regimen-for-treatment-of-refractory-non-hodgkin-s-lymphoma
#7
Shi-Bin Yan, Zhong-Guang Chen, De-Liang Ma, Xin Lyu, Yan-Li Wang, Shi-Bing Chen, Gui-Tao Jie
OBJECTIVE: To explore the clinical efficacy of GEMOX regimen on patients with refractory non-hodgkin's lymphoma. METHODS: Eighty-two cases of non-Hodgkin's lymphoma were divided into 2 groups: gemcitabine+oxaliplation(Gem+Oxa) group (42 cases) and vinorelbine+oxaliplatin(Vin+Oxa) group (40 cases) according to chemotherapy regimens. The clinical efficacy, side effects, progression-free survival situation in 2 groups were compared. RESULTS: There was no significant difference on the clinical effects of 2 groups (P>0...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28874597/risk-of-febrile-neutropenia-associated-with-select-myelosuppressive-chemotherapy-regimens-in-a-large-community-based-oncology-practice
#8
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H Page, Chun Chao
Background: NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based primarily on clinical trial evidence. Many chemotherapy regimens, however, remain unclassified by NCCN or lack FN incidence data in real-world clinical practice. Patients and Methods: We evaluated incidence proportions of FN and grade 4 and 3/4 neutropenia during the first chemotherapy course among patients from Kaiser Permanente Southern California who received selected chemotherapy regimens without well-established FN risk...
September 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28614905/long-term-follow-up-of-chemoimmunotherapy-with-rituximab-oxaliplatin-cytosine-arabinoside-dexamethasone-road-in-patients-with-relapsed-cd20-b-cell-non-hodgkin-lymphoma-results-of-a-study-of-the-mayo-clinic-cancer-center-research-consortium-mccrc-mc0485-now
#9
Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, Paul J Kurtin, Levi D Pederson, Dennis F Moore, Nassim H Nabbout, Daniel A Nikcevich, Kendrith M Rowland, Axel Grothey
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 - 5; oxaliplatin 130 mg/m2 IV day 2; cytarabine 2000 mg/m2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4...
October 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28454330/high-bim-mrna-levels-are-associated-with-longer-survival-in-advanced-gastric-cancer
#10
Nandie Wu, Ying Huang, Zhengyun Zou, Ana Gimenez-Capitan, Lixia Yu, Wenjing Hu, Lijing Zhu, Xia Sun, Jose Javier Sanchez, Wenxian Guan, Baorui Liu, Rafael Rosell, Jia Wei
Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS)...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28381416/a-phase-2-3-multicenter-randomized-open-label-study-to-compare-the-efficacy-and-safety-of-lenalidomide-versus-investigator-s-choice-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
#11
RANDOMIZED CONTROLLED TRIAL
Myron S Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M Linton, Nina Wagner-Johnston, Randy D Gascoyne, Graham W Slack, Pierre Brousset, David A Eberhard, Francisco J Hernandez-Ilizaliturri, Gilles Salles, Thomas E Witzig, Pier Luigi Zinzani, George W Wright, Louis M Staudt, Yandan Yang, P Mickey Williams, Chih-Jian Lih, Jacqueline Russo, Anjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, Ian D Lewis
Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin)...
August 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28215935/comparative-study-of-l-asparaginase-based-lop-regimen-over-chop-regimen-before-radiotherapy-for-stage-iie-extranodal-nasal-type-nk-t-cell-lymphoma-a-study-of-2-centers
#12
MULTICENTER STUDY
Limin Huang, Bin Yuan, Haixia Wu, Hongliang Chu, Yayun Liu, Shuang Wu, Hong Li, He Lu, Hui Chen
BACKGROUND: In this study we evaluated the efficacy of an L-asparaginase-based LOP (L-asparaginase, vincristine, and dexamethasone) regimen in extranodal Natural Killer (NK)/T-cell lymphoma (ENKTL) patients in the Guizhou province of China. PATIENTS AND METHODS: Forty-eight patients were treated with the LOP (L-asparaginase, vincristine and dexamethasone) regimen chemotherapy (CT) and 32 patients with the CHOP (cyclophosphamide, tetrahydropyanyl adriamycin, vincristine, and prednisone) regimen...
March 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28194060/retrospective-study-of-pegaspargase-gemicitabine-oxaliplatin-and-dexamethasone-peg-gemod-as-a-first-line-therapy-for-advanced-stage-extranodal-nk-t-cell-lymphoma
#13
Yi-Yun Yao, Yong Tang, Yan Zhuang, Li-Fang Zou, Hong-Ju Dou, Lei Wang, Qi Zhu
This study was conducted to retrospectively investigate the efficacy and safety of pegaspargase, gemicitabine, oxaliplatin and dexamethasone (Peg-GemOD) combination chemotherapy as a first-line therapy for advanced-stage extranodal NK/T cell lymphoma (ENKTL). Eighteen patients with newly diagnosed stage III/IV ENKTL were subjected to 3-6 cycles of Peg-GemOD chemotherapy. After 3 cycles of therapy, the overall response rate was 67 % (12/18) with a complete response rate of 28 % (5/18) and a partial response rate of 39 % (7/18)...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28093003/outcome-for-patients-with-relapsed-refractory-aggressive-lymphoma-treated-with-gemcitabine-and-oxaliplatin-with-or-without-rituximab-a-retrospective-multicentre-study
#14
Vijay Dhanapal, Menaka Gunasekara, Chia Lianwea, Robert Marcus, Corinne De Lord, Stella Bowcock, Stephen Devereux, Piers Patten, Deborah Yallop, David Wrench, Paul Fields, Shireen Kassam
The treatment of relapsed aggressive lymphoma remains a challenge. Platinum-containing chemotherapy is standard of care. Gemcitabine/oxaliplatin (Gem-Ox) with or without rituximab (R) is an outpatient regimen with a favorable toxicity profile. This retrospective 'real world' study reports outcomes for 44 unselected patients with relapsed/refractory aggressive lymphoma treated with Gem-Ox ± R. 41% had primary refractory disease. The overall response rate (ORR) was 43% with a complete response (CR) of 30%...
September 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27917702/effectiveness-of-pegaspargase-gemcitabine-and-oxaliplatin-p-gemox-chemotherapy-combined-with-radiotherapy-in-newly-diagnosed-stage-ie-to-iie-nasal-type-extranodal-natural-killer-t-cell-lymphoma
#15
Wen Wei, Ping Wu, Li Li, Zhi-Hui Zhang
PURPOSE: Extranodal natural killer/T-cell lymphoma (ENKTL), nasal-type, is a distinct subtype of non-Hodgkin lymphoma. ENKTL is sensitive to radiotherapy, but the prognosis is poorer than those of other types of early stage lymphoma. To date, optimal treatment strategies for patients with early stage ENKTL have not been fully defined. METHODS: We retrospectively investigated the efficacy and safety of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) combined with different dose radiotherapy (RT) in the treatment of 35 newly diagnosed, stage IE to IIE ENKTL patients at our institution from October 2011 to September 2015...
July 2017: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27757832/pixantrone-a-review-in-relapsed-or-refractory-aggressive-non-hodgkin-s-lymphoma
#16
REVIEW
Gillian M Keating
Pixantrone (Pixuvri(®)) is an aza-anthracenedione with a novel mode of action that is conditionally approved in the EU for use as monotherapy in adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL). In the randomized, open-label, multinational, phase 3 PIX301 trial in patients with multiply relapsed or refractory aggressive NHL, the complete response (CR) plus unconfirmed CR (uCR) rate at the end of treatment (primary endpoint) was significantly higher with intravenous pixantrone monotherapy than with a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone or gemcitabine)...
October 2016: Drugs
https://www.readbyqxmd.com/read/27377614/comparative-toxicities-of-3-platinum-containing-chemotherapy-regimens-in-relapsed-refractory-lymphoma-patients
#17
COMPARATIVE STUDY
F Tixier, F Ranchon, A Iltis, N Vantard, V Schwiertz, E Bachy, F Bouafia-Sauvy, C Sarkozy, J F Tournamille, E Gyan, G Salles, C Rioufol
Optimal salvage chemotherapy regimen for patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma remains unclear but often based on platinum regimens. This retrospective study assesses in real life the toxicities profiles of patients with relapsed or refractory lymphoma treated with DHA (dexamethasone, high dose aracytine cytarabine) plus platinum salt (dexamethasone-High dose aracytine (cis)platin (DHAP), dexamethasone-High dose aracytine carboplatin (DHAC), or dexamethasone-High dose aracytine Oxaliplatin (DHAOX)), from February 2007 to May 2013 in 2 French hospitals...
December 2017: Hematological Oncology
https://www.readbyqxmd.com/read/27354597/enhanced-tlr4-expression-on-colon-cancer-cells-after-chemotherapy-promotes-cell-survival-and-epithelial-mesenchymal-transition-through-phosphorylation-of-gsk3%C3%AE
#18
Yoon Hee Chung, Daejin Kim
BACKGROUND: Phosphorylation of glycogen synthase kinase 3β (GSK3β) by phosphatidyl-inositide 3-kinase (PI3K)/protein kinase B (AKT) or inhibition of GSK3β with small-molecule inhibitor attenuates cell survival and proliferation and increases apoptosis in most cancer cell lines. In this study, we investigated the role of phosphorylated GSK3β activated by enhanced toll-like receptor 4 (TLR4) expression in drug-treated colon cancer cells as a model of post-chemotherapy cancer cells. MATERIALS AND METHODS: The effect of TLR4 stimulation on metastasis and apoptosis in drug-exposed colon cancer cells was determined by real-time polymerase chain reaction (PCR) and immunoblotting...
July 2016: Anticancer Research
https://www.readbyqxmd.com/read/27239738/efficacy-and-tolerance-of-pegaspargase-gemcitabine-and-oxaliplatin-with-sandwiched-radiotherapy-in-the-treatment-of-newly-diagnosed-extranodal-nature-killer-nk-t-cell-lymphoma
#19
Xiao-Mei Jing, Zhi-Hui Zhang, Ping Wu, Shi-Chuan Zhang, Yuan-Rong Ren, Zhu-Juan Xiong, Wen Wei, Lei Luo, Li Li
Extranodal nature killer (NK)/T cell lymphoma (ENKL), nasal type, is a highly aggressive and heterogeneous disease. Here we report a retrospective study of 38 newly-diagnosed ENKL patients treated with pegaspargase, gemcitabine, oxaliplatin (P-Gemox) and sandwiched radiotherapy in our department during 2012-2016. A median of 4 (range, 2-6) (total=141) cycles of P-Gemox were administered. Interim restaging after at least 2 cycles showed complete remission (CR) rate of 23.68%, partial remission (PR) rate of 63...
August 2016: Leukemia Research
https://www.readbyqxmd.com/read/27220900/efficacy-of-the-gemox-r-regimen-leads-to-the-identification-of-oxaliplatin-as-a-highly-effective-drug-against-mantle-cell-lymphoma
#20
Antònia Obrador-Hevia, Margalida Serra-Sitjar, José Rodríguez, Lamiae Belayachi, Leyre Bento, Marta García-Recio, Jose María Sánchez, Priam Villalonga, Antonio Gutiérrez, Silvia Fernández de Mattos
Mantle Cell Lymphoma (MCL) is an aggressive lymphoma subtype that accounts for 6-8% of non-Hodgkin lymphomas. The disease is mostly incurable and characterized by a continuous pattern of relapse. Major changes have recently been implemented in the management of MCL, but continuous relapses still mark this disease as a challenge for clinicians. We previously reported the efficacy of GemOx-R (Gemcitabine, Oxaliplatin and Rituximab) in patients with refractory and relapsing MCL. We present results for a larger series with longer follow-up and including high-risk frontline patients, showing an overall response rate of 83%...
September 2016: British Journal of Haematology
keyword
keyword
9105
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"